| Literature DB >> 27134269 |
Joseph F Merola1, April W Armstrong2, Ami Saraiya2, John Latella2, Amit Garg2, Kristina Callis Duffin2, Alice B Gottlieb2.
Abstract
Previous publications have described the International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, participating pharmaceutical industry partners, payers, and regulatory agencies. The goal of IDEOM is to create patient-centered, validated measures of dermatologic disease progression and treatment efficacy for use in both clinical trials and clinical practice. We provide an update of IDEOM activities as of our 2015 IDEOM meeting in Washington, DC, USA.Entities:
Keywords: IDEOM; OMERACT; OUTCOME MEASURES; PSORIASIS
Mesh：
Year: 2016 PMID： 27134269 DOI： 10.3899/jrheum.160114
Source DB: PubMed Journal: J Rheumatol ISSN： 0315-162X Impact factor: 4.666